AgomAb Therapeutics NV’s Quiet Period To Expire on March 18th (NASDAQ:AGMB)

AgomAb Therapeutics’ (NASDAQ:AGMB) quiet period is set to expire on Wednesday, March 18th. AgomAb Therapeutics had issued 12,500,000 shares in its public offering on February 6th. The total size of the offering was $200,000,000 based on an initial share price of $16.00. During the company’s quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AGMB. Wall Street Zen upgraded AgomAb Therapeutics to a “hold” rating in a research note on Tuesday, February 17th. JPMorgan Chase & Co. began coverage on AgomAb Therapeutics in a research note on Tuesday, March 3rd. They issued an “overweight” rating and a $32.00 price objective for the company. Morgan Stanley started coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “overweight” rating and a $28.00 target price for the company. Zacks Research raised AgomAb Therapeutics to a “hold” rating in a research note on Wednesday, March 4th. Finally, Leerink Partners started coverage on AgomAb Therapeutics in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $36.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

AgomAb Therapeutics Stock Down 4.7%

Shares of AgomAb Therapeutics stock opened at $13.75 on Wednesday. AgomAb Therapeutics has a twelve month low of $12.66 and a twelve month high of $17.45.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.